EA202091273A1 - Композиции на основе силиката циркония для длительного применения и способы их применения - Google Patents

Композиции на основе силиката циркония для длительного применения и способы их применения

Info

Publication number
EA202091273A1
EA202091273A1 EA202091273A EA202091273A EA202091273A1 EA 202091273 A1 EA202091273 A1 EA 202091273A1 EA 202091273 A EA202091273 A EA 202091273A EA 202091273 A EA202091273 A EA 202091273A EA 202091273 A1 EA202091273 A1 EA 202091273A1
Authority
EA
Eurasian Patent Office
Prior art keywords
zirconium silicate
application
methods
long
compositions based
Prior art date
Application number
EA202091273A
Other languages
English (en)
Inventor
Дональд Джеффри Кейзер
Альваро Ф. Гиллем
Original Assignee
Зс Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58227650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202091273(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зс Фарма, Инк. filed Critical Зс Фарма, Инк.
Publication of EA202091273A1 publication Critical patent/EA202091273A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/02—Processes using inorganic exchangers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C01B39/06—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis
    • C01B39/08—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis the aluminium atoms being wholly replaced
    • C01B39/085—Group IVB- metallosilicates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к композициям на основе силиката циркония, характеризующимся содержанием свинца, которое составляет менее 0,6 ppm, и к способам изготовления силиката циркония при объемах реактора, превышающих 200 л, с содержанием свинца менее 1,1 ppm. Значения содержания свинца в силикате циркония согласно настоящему изобретению находятся на уровнях, которые считаются приемлемыми для длительного использования, с учетом требований дозирования для силиката циркония.
EA202091273A 2015-10-14 2016-10-10 Композиции на основе силиката циркония для длительного применения и способы их применения EA202091273A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/883,428 US9592253B1 (en) 2015-10-14 2015-10-14 Extended use zirconium silicate compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
EA202091273A1 true EA202091273A1 (ru) 2021-02-03

Family

ID=58227650

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091273A EA202091273A1 (ru) 2015-10-14 2016-10-10 Композиции на основе силиката циркония для длительного применения и способы их применения
EA201890875A EA035890B1 (ru) 2015-10-14 2016-10-10 Композиции на основе силиката циркония для лечения гиперкалиемии

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201890875A EA035890B1 (ru) 2015-10-14 2016-10-10 Композиции на основе силиката циркония для лечения гиперкалиемии

Country Status (18)

Country Link
US (4) US9592253B1 (ru)
EP (1) EP3362456A4 (ru)
JP (1) JP6546700B2 (ru)
CN (2) CN113143958A (ru)
AR (1) AR106369A1 (ru)
AU (1) AU2016338753C1 (ru)
CA (1) CA3000950C (ru)
CL (1) CL2018000916A1 (ru)
CR (1) CR20180276A (ru)
EA (2) EA202091273A1 (ru)
HK (1) HK1254808A1 (ru)
IL (1) IL258478B (ru)
MX (1) MX2018004440A (ru)
MY (1) MY187088A (ru)
PH (1) PH12018500786A1 (ru)
TW (1) TWI742004B (ru)
WO (1) WO2017066128A1 (ru)
ZA (1) ZA201803095B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012214224B2 (en) 2011-02-11 2016-03-17 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
WO2019092179A1 (en) * 2017-11-10 2019-05-16 Sandoz Ag Pharmaceutical compositions comprising zs-9
AU2020235911A1 (en) 2019-03-13 2021-11-04 Astrazeneca Ab Potassium-binding agents for use in hemodialysis patients
CN117342570A (zh) * 2023-09-04 2024-01-05 杭州国瑞生物科技有限公司 一种环硅酸锆钠的a晶型及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE21224E (en) 1939-10-03 Coherent zirconium silicates
US3947279A (en) 1971-12-23 1976-03-30 Owens-Illinois, Inc. Thermally crystallizable glasses possessing precision controlled crystallization and flow properties and process of producing same
US4581141A (en) 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
FR2444005A1 (fr) 1978-12-15 1980-07-11 Ugine Kuhlmann Procede industriel de fabrication en semi-continu de zeolithe a
US4943545A (en) 1987-06-08 1990-07-24 Mobil Oil Corporation Activation of zeolites
US5015453A (en) 1989-04-28 1991-05-14 W. R. Grace & Co.-Conn. Crystalline group IVA metal-containing molecular sieve compositions
US5338527A (en) 1992-08-20 1994-08-16 Uop Zirconium silicate composition, method of preparation and uses thereof
PL172190B1 (pl) 1992-10-28 1997-08-29 Crosfield Joseph & Sons Bezpostaciowa krzemionka i sposób wytwarzania bezpostaciowej krzemionki PL PL PL
US5518707A (en) 1994-10-24 1996-05-21 Uop Metallo germanates
WO1998052239A1 (en) 1997-03-12 1998-11-19 Japan As Represented By Director General Of Agency Of Industrial Science And Technology Separator for battery and alkali secondary battery using the same
IT1283284B1 (it) 1996-03-21 1998-04-16 Eniricerche Spa Zeolite ers-10 e procedimento per la sua preparazione
FR2750893B1 (fr) 1996-07-12 1998-10-30 Elf Aquitaine Procede de synthese de zeolithe avec agitation homogene du milieu, dispositif et application
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US6007790A (en) 1998-08-13 1999-12-28 Uop Llc Family of microporous indium silicate compositions
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US7041274B2 (en) 1999-10-22 2006-05-09 Intevep, S.A. Aluminosilicate compositions, preparation and use
US20020061521A1 (en) 2000-01-31 2002-05-23 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6379641B1 (en) 2000-05-01 2002-04-30 Uop Llc Microporous rare earth silicates and method of producing same
US6596254B1 (en) 2000-06-12 2003-07-22 Sandia Corporation Niobate-based octahedral molecular sieves
US20040105895A1 (en) 2001-02-06 2004-06-03 Ash Stephen R Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
US6814871B1 (en) 2001-07-13 2004-11-09 Uop Llc Process for removing pollutants from aqueous streams
US6689335B1 (en) 2002-12-19 2004-02-10 Eastman Kodak Company Silver ion sequester and release agent
JP4671419B2 (ja) 2003-12-15 2011-04-20 旭化成ケミカルズ株式会社 多孔性成形体及びその製造方法
KR101228233B1 (ko) 2004-03-30 2013-01-31 리립사, 인크. 이온 결합 중합체 및 이의 용도
MX2007007881A (es) 2004-12-28 2007-09-12 Renal Solutions Inc Metodo para sintetizar particulas de fosfato de zirconio.
KR101005388B1 (ko) 2005-06-14 2010-12-30 아사히 가세이 케미칼즈 가부시키가이샤 수처리 장치 및 수처리 방법
DE112006002618T5 (de) 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Verfahren und Zusammensetzungen zum selektiven Entfernen von Kaliumionen aus dem Gastrointestinaltrakt eines Säugers
AU2006294455B2 (en) 2005-09-30 2013-06-20 Relypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
US7297318B2 (en) * 2005-11-17 2007-11-20 J.M. Huber Corporation Method of removing heavy metals from silicate sources during silicate manufacturing
US7201885B1 (en) * 2005-11-17 2007-04-10 J.M. Huber Corporation Method of removing heavy metals from silicate sources during silicate manufacturing
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007127390A2 (en) 2006-04-28 2007-11-08 Biolife, L.L.C. Materials and methods for wound treatment
US8093350B2 (en) 2007-01-03 2012-01-10 Insilicotech Co., Ltd Coordination polymer crystal with porous metal-organic frameworks and preparation method thereof
ES2304890B1 (es) 2007-04-03 2009-10-30 Universidad De Zaragoza Procedimiento de obtencion de esferas de titanosilicato.
EP3138822B1 (en) 2008-02-26 2023-07-26 Corning Incorporated Fining agents for silicate glasses
US20100104527A1 (en) 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
FI3431094T3 (fi) 2008-08-22 2023-03-20 Vifor Int Ltd Silloitettuja kationinvaihtopolymeerejä, koostumuksia ja käyttö hyperkalemian hoidossa
US8865121B2 (en) 2009-06-18 2014-10-21 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
US20120070468A1 (en) 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
AU2012214224B2 (en) * 2011-02-11 2016-03-17 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
US8710271B2 (en) 2011-04-08 2014-04-29 Basf Se Process for the production of an acylation catalyst
US9527751B2 (en) 2011-11-11 2016-12-27 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material of the CHA-type structure
EP2812281B1 (en) 2012-02-06 2020-07-29 Basf Se Iron- and copper-containing zeolite beta from organotemplate-free synthesis and use thereof in the selective catalytic reduction of nox
US9475041B2 (en) 2012-04-24 2016-10-25 Basf Se Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds
AU2013290141A1 (en) * 2012-07-11 2015-02-05 Alvaro F. Guillem Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
CA2891053C (en) * 2012-10-22 2020-12-01 ZS Pharma, Inc. Microporous zirconium silicate for treating hyperkalemia
JP6280636B2 (ja) * 2013-04-05 2018-02-14 ズィーエス・ファーマ，インコーポレーテッド カリウムの低減と慢性腎臓病及び／または慢性心臓病の治療のための微多孔性ケイ酸ジルコニウム及び利尿剤
CN106170283B (zh) * 2013-11-08 2019-08-20 Zs制药公司 用于治疗高钾血症的微孔硅酸锆
MX2016007474A (es) * 2013-12-10 2016-10-03 Zs Pharma Inc Silicato de zirconio para tratar hipercalemia sin co-administrar litio.
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof

Also Published As

Publication number Publication date
CR20180276A (es) 2018-09-19
US20190365800A1 (en) 2019-12-05
CA3000950A1 (en) 2017-04-20
CN108137620B (zh) 2021-05-18
PH12018500786A1 (en) 2018-10-29
EP3362456A1 (en) 2018-08-22
US9592253B1 (en) 2017-03-14
US10300087B2 (en) 2019-05-28
TWI742004B (zh) 2021-10-11
CN113143958A (zh) 2021-07-23
MY187088A (en) 2021-08-30
US11738044B2 (en) 2023-08-29
CL2018000916A1 (es) 2018-08-17
IL258478B (en) 2020-09-30
CN108137620A (zh) 2018-06-08
JP2018530596A (ja) 2018-10-18
ZA201803095B (en) 2019-11-27
EA035890B1 (ru) 2020-08-27
AU2016338753B2 (en) 2019-04-18
JP6546700B2 (ja) 2019-07-17
WO2017066128A1 (en) 2017-04-20
TW201717972A (zh) 2017-06-01
EA201890875A1 (ru) 2018-11-30
AU2016338753A1 (en) 2018-04-12
AU2016338753C1 (en) 2019-08-08
KR20180067614A (ko) 2018-06-20
US20170151279A1 (en) 2017-06-01
MX2018004440A (es) 2018-07-06
US20240009229A1 (en) 2024-01-11
CA3000950C (en) 2023-10-31
HK1254808A1 (zh) 2019-07-26
BR112018007189A2 (pt) 2018-10-16
IL258478A (en) 2018-05-31
AR106369A1 (es) 2018-01-10
EP3362456A4 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
EA202091273A1 (ru) Композиции на основе силиката циркония для длительного применения и способы их применения
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MY187540A (en) Compounds active towards bromodomains
PH12017500745A1 (en) Bromodomain inhibitors
MX370903B (es) Composiciones de ácido percarboxílico estables y sus usos.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PL409829A1 (pl) Płyn z cytyzyną do elektronicznych papierosów
EA202090683A2 (ru) Способы и композиции для лечения рака
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA201690036A1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
PH12016500874A1 (en) Two part oxidizing system for oral care compositions
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201692569A1 (ru) Полимиксины с низкой степенью замещения и композиции, их содержащие
PH12017501897A1 (en) 2-thiopyrimidinones
MX365952B (es) Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa.
MX2016004961A (es) Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
EE201400004A (et) Meetod kõrge aktiivkloori sisaldusega desinfektsioonivahendi saamiseks läbivoolu diafragmaelektrolüüserist
MX2019010572A (es) Composicion que comprende avelumab.